A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine for patients with residual invasive HER2-positive breast cancer following neoadjuvant taxane-based and HER2-targeted therapy including trastuzumab, who are at high risk of disease recurrence.

Check your eligibility (clinicaltrials.gov)